DDInter1036 DDInter1376
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Lenvatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lenvatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venlafaxine
Lenvatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tipiracil
Lenvatinib {u} may lead to a major life threatening interaction when taken with {v} Vandetanib
Lenvatinib {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Lenvatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Tipiracil
Lenvatinib may lead to a major life threatening interaction when taken with Vandetanib
Lenvatinib may lead to a major life threatening interaction when taken with Ivosidenib